By Jeffry John Aufderheide | February 3rd, 2011
Vaccines are safe and effective with a one-in-a-million-chance for an adverse reaction. At least that is what parents are told repeatedly by mainstream media doctors and scientists.
In January of 2010, Payne et al. describes an orally administered, live, attenuated, pentavalent human-bovine RotaTeq vaccine given to a two month old child.
Approximately 10 days following the vaccine, his older unvaccinated sibling required unexpected emergency treatment attributed to gastroenteritis.
Based on the case report in the Journal of the American Academy of Pediactrics, the vaccine-derived rotavirus was transmitted from the vaccinated infant to his older, unvaccinated sibling that lead to ‘symptomatic rotavirus gastroenteritis’.
Payne and colleagues mentioned although this may possibly not be a ‘common phenomenon’, they stated, “Transmission of RotaTeq strains to unvaccinated contacts was not evaluated in the pivotal clinical trials and, to our knowledge, has not been reported during the postlicensure period.”
To reflect Payne’s observation, the heading in the vaccine insert “Shedding and Transmission ” was added in September of 2010.
Listed as common side effects from the RotaTeq vaccine are diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.
The vaccine inserts continues to report, “No safety data no safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised… or infants with a history of gastrointestinal disorders.”
RotaTeq was approved for pediatric use in 2006. The vaccine is manufactured by Merck and Company. Paul Offit, the Chief of Infectious Diseases at the Children’s Hospital of Philadelphia, has a patent on the RotaTeq vaccine.
Leave a Reply